Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

Summary

The purpose of this study is to test whether Daratumumab-SC, a drug that eliminates antibody-producing plasma cells, can effectively lower the level of preformed antibodies in patients awaiting heart transplantation. These preformed antibodies limit the number of donor hearts that are compatible for the patients. If Daratumumab-SC can effectively remove preformed, donor-specific antibodies, then highly allosensitized patients will have more compatible hearts available to them, potentially decreasing transplant waitlist time and reducing mortality.

Timeline

Start

2021-07-01

Primary completion

2024-01-26

Completion

2024-01-26

Drugs

Indications